Seres Therapeutics (MCRB) Lifted to Hold at BidaskClub

Seres Therapeutics (NASDAQ:MCRB) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Zacks Investment Research upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $18.00.

Shares of Seres Therapeutics (NASDAQ MCRB) opened at $9.81 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53. The stock has a market cap of $391.52 and a PE ratio of -4.63. Seres Therapeutics has a one year low of $7.90 and a one year high of $17.42.

Several institutional investors have recently made changes to their positions in MCRB. ARK Investment Management LLC grew its position in shares of Seres Therapeutics by 82.0% during the fourth quarter. ARK Investment Management LLC now owns 1,625,501 shares of the biotechnology company’s stock worth $16,483,000 after buying an additional 732,579 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Seres Therapeutics by 48.7% during the fourth quarter. Renaissance Technologies LLC now owns 911,200 shares of the biotechnology company’s stock worth $9,240,000 after buying an additional 298,300 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $2,308,000. Citadel Advisors LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $1,396,000. Finally, Ark Investment Management LLC grew its position in shares of Seres Therapeutics by 21.5% during the second quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after buying an additional 135,276 shares in the last quarter. 81.78% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Seres Therapeutics (MCRB) Lifted to Hold at BidaskClub” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://ledgergazette.com/2018/02/24/seres-therapeutics-mcrb-lifted-to-hold-at-bidaskclub.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply